Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases

By WebmasterSeptember 4, 2018November 1st, 2024No Comments

Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases

See more here

Previous PostPalvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors
Next PostCohero Health Announces Additions to Executive Leadership Team

Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostPalvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors

Next PostCohero Health Announces Additions to Executive Leadership Team